Calling for submissions for the 2022 volume for the following article types: Original Research, Study Characteristics, Clinical Studies, Systematic Reviews, Reviews, Mini Reviews, Case Series, and Commentaries
In the Oncology section, we consider for publication the latest advances in:
Annals of Medicine
Q1 Impact Factor Best Quartile
Two-Year Impact Factor 4.709
Five-Year Impact Factor 4.554
PubMed Central® and MEDLINE® Indexed
Meet the Section Editors
Rakesh Kumar, Rajiv Gandhi Centre for Biotechnology, India
Dr. Kumar is a Distinguished Professor and National Chair in Cancer Research at the Rajiv Gandhi Centre for Biotechnology-India, while holding visiting/adjunct professorships at the Virginia Commonwealth University School of Medicine and Rutgers NJ Medical Center. Dr. Kumar is a cancer biologist with over 34 years of experience in basic, translational and preclinical cancer research. He has served as a faculty member and administrator at the US Medical and Cancer Centers, including Memorial Sloan-Kettering Cancer Center and UT MD Anderson Cancer Center. For 25 years, Dr. Kumar has been actively contributed to the peer-review process for multiple national and international funding agencies. Dr. Kumar has shared his cancer research experience by delivering over 270 invited lectures at national and international scientific forums, training over 65 students, physician scientists and postdoctoral fellows, and editing or co-editing eight books or thematic volumes in cancer research and therapeutics.
Professor Hao Zhang, MD, Ph.D., Institute of Precision Cancer Medicine and Pathology, Jinan University Medical College, Guangzhou, China
Dr. Zhang is a Professor at Jinan University Medical College, and Director and Founder of The Institute of Precision Cancer Medicine and Pathology. Dr. Zhang is a physician scientist with a career as a cancer research scientist in addition to his clinical experience as an oncologist and endocrinologist. Dr. Zhang received his Medical Degree from China Medical University in China and his Ph.D. from Shimane Medical University in Japan. He has worked at Baylor College of Medicine, UT MD Anderson Cancer Center and Shantou University Medical College. Dr. Zhang has published more than 70 peer-reviewed papers and edited /co-edited 3 books and contributed 6 book chapters in cancer biology and clinical oncology. He is the leading PI for more than 5 clinical trials. Dr. Zhang is actively engaged in the scientific community. He has served as editorial board member for several academic journals. He also regularly reviews national and international grants, and has been regularly invited to review academic journals. He is a Leadership Member or Senior Member of several academic associations of cancer biology and oncology in China. Dr. Zhang established the CACA TBM Society for Exosomes and Microvesicles (CSEMV) In 2017 and has served as Chair since then.
Why is Annals of Medicine the best publication for your research?
Fully open access, general medical journal publishing articles under a CC BY license, allowing maximum sharing and reuse of articles to our international readership;
Publishing all scientifically valid research, including reporting of negative and null data, from translational to clinical research in all disciplines and therapy areas;
Led by an international editorial team of subject experts who ensure a constructive and rigorous peer review process;
Your research is promoted via a tailored, multi-channel approach to maximize visibility, readership and impact.
To help improve your manuscript and prepare it for submission, Taylor & Francis provides a range of editing services such as English Language Editing, which will ensure that your article is free of spelling and grammar errors, Translation, and Artwork Preparation.